

Postural Orthostatic Tachycardia Syndrome

D. Elizabeth Le, MD, FACC, FASE, FAHA Associate Professor of Medicine April 10, 2025

Disclosures

- No actual or potential conflicts of interest in relation to this program or presentation to disclose.
- There are NO FDA-approved medications for POTS
- All medications discussed are for off-label use but have been studied in clinical trials.
- The contents do not represent the views of the U.S. Department of Veterans Affairs or the U.S. government.




Objectives

- Recognize the criteria to diagnose postural orthostatic tachycardia syndrome (POTS)
- Select the appropriate nonpharmacologic and pharmacologic treatment for POTS




Demographics





Lei LY et al. Cleveland Clinic J Med. 2019;86:333-344. Aboseit DO et al. Cleveland Clinic J Med. 2023;90:439-477. Map by WaterproofPaper.com



In the News.....

The Washington Post

Breaking News

Trending Now 5 minutes ago

A mysterious condition is striking young, highly trained athletes

First described more than 150 years ago, POTS has proliferated since the coronavirus pandemic. The syndrome tends to strike suddenly, leaving previously healthy people unable to function, with no clear cause. In recent years, doctors have noticed a curious and disproportionate subset of patients: female athletes at peak fitness.

They're young and athletic. They're also ill with a condition called POTS.

Since covid-19, diagnoses have increased, researchers and doctors report





Katie Ledecky POTS: What to Know About Her Symptoms and Treatment (today.com)




Prevalence – Long COVID





- ~ 103 million cases
- ~ 1.12 million deaths
- ~ 15.7 million Long COVID (14-18%)
- 2-14% of survivors developed POTs
- 9-61% experienced POTS-like symptoms within 6-8 months
- POTS rate 5-fold higher with infection than with vaccination
- Women > Men
- Whites + Hispanics > Blacks and Asians
- Lower prevalence in higher educated and higher income groups







Why is POTS a challenging diagnosis?

- Heterogeneous presentation
 - Underdiagnosed or misdiagnosed
- Atypical features overlap with other medical conditions
- Co-existing psychiatric conditions
 - Attributed to chronic anxiety or panic disorders
- Lack of clinician familiarity with the condition
- Multiple mechanisms



POTS – Patients' Experience

Self-reported patient survey from UK, N=4,835

Patients saw an average of 7 physicians before POTS diagnosis

Average of 4 years before correct diagnosis of POTS is made

2 out of 3 patients report at least 10 different symptoms


- Median time to diagnosis ~ 6-72 months
- 27% saw >10 physicians
- 83% given psychiatric diagnosis before POTS diagnosis

Can be debilitating and negatively affect quality of life Challenging diagnosis but can be helpful if confirmed



Case - History

23 yo female with history of migraine and POTS diagnosed in 2019, referred to general cardiology clinic for management of POTS.





Case - History

Vitals

• Standing: Pulse 133 BP 130/65


Standing > 3min
 Pulse 88
 BP 133/68

Exam: no murmur, PIC in right UE with erythema around bandage

ECG: NSR

 24hour Holter Monitor: Mean HR 83, range 56-83 bpm, sinus arrhythmia, no ectopy

TTE: normal





Historical Perspective

~1860 (Da Costa)

Irritable heart syndrome

1918 (Lewis)

1941 (Wood)

Soldier's heart

Da Costa syndrome

1982

(Rosen and Cryer)

Postural tachycardia syndrome

Disabling tachycardia upon standing without orthostatic hypotension

1986

(Fouad)


Idiopathic hypovolemia

Small degree of hypotension

1993

(Schondorf and Low)

Current definition of POTS



Dr. Jacob M. Da Costa https://www.civilwarmed.org/irritableheart/



Symptom Characteristics

- Palpitations or tachycardia onset
 - 12.5% Acute (<1 month)
 - 13.8% Subacute (1-3 months)
 - -5.9% Insidious (>3 months)
- Frequency
- Impact on function and quality of life



Symptoms

Postural Cardiac Symptoms

- Lightheadedness (99%)
- Tachycardia (97%)
- Presyncope (94%)
- Shortness of breath (88%)
- Palpitations (87%)
- Chest discomfort

Noncardiac Symptoms

- Mental clouding (brain fog)
- Tremulousness
- Blurred or tunnel vision
- Nausea

Observed with chronic autoimmune disease

- Headache
- Sleep disturbances
- Malaise
- Abdominal pain, heartburn, diarrhea, constipation (last hours, multiple times/week)



Symptoms Context

Triggers

- Infection
 - COVID-19 (22%)
- Vaccination
 - HPV
- Surgery (12%)
- Trauma
- Pregnancy (9%)
- Childbirth
- Prolonged period of inactivity

Exacerbation

- Heat
- Fever
- Dehydration
- Morning hours
- Non-dippers
- Strong emotions
- Alcohol
- Menstruation
 - Worse pre or early cycle when estrogen and progesterone are low or decreasing



Dietary and Exercise Habits & Culprit Medications

Diet and Functional Status

- Diet
 - Amount of salt and volume of water intake
 - Size of meals
- Exercise tolerance
 - Quantify amount of activity and reduction of activity over a period of time
 - List physical activities that no longer can be performed

Medications that can exacerbate POTs

- Antidepressants
 - Serotonin-norepinephrine reuptake inhibitors
 - Monoamine oxidase inhibitors
- Antipsychotics (phenothiazines)
- Anticholinergics
- ADHD medications
- Diuretics
- Vasodilators and venodilators
- Oral contraceptive pills that contain antimineralocorticoid (drospirenone)
- Stimulants (caffeine, nicotine)



Detailed Autonomic Review of Systems

Musculoskeletal

Muscle fatigue

Weakness

Pain

Gastrointestinal

Nausea

Bloating

Dysmotility

Gastroparesis

Diarrhea

Constipation

Pain

Irritable bowel syndrome

Weight loss

Nervous System

Headache

Migraine

Cognitive impairment

Brain fog

Photophobia

Phonophobia

Blurred vision

Neuropathic pain

Sleep disorder

Involuntary movement

Respiratory

Short of breath

Hyperventilation

Bronchial asthma

Aboseit DO et al. Cleveland Clinic J Med. 2023;90:439-477. Sebastian SA et al. Curr Prob Cardiol. 2022;47:1-24



Detailed Autonomic Review of Systems

Urogenital

Bladder dysfunction

Polyuria

Nocturia

Urgency

Frequency

Skin

Rash

Erythema

Petechiae

Telangiectasia

Diaphoresis

Flushing

Pallor

Dry eyes and mouth

Sudomotor dysregulation

Psychiatric

Anxiety

Depression

Panic attacks

Suicidal ideation

Somatic hypervigilance

Catastrophyzing personality

Aboseit DO et al. Cleveland Clinic J Med. 2023;90:439-477.

Sebastian SA et al. Curr Prob

Cardiol. 2022;47:1-24



POTS vs. Postural Tachycardia



Upright Tachycardia

- ≥30 bpm >19 years old
- ≥40 bpm 12-19 years old
- Sustained tachycardia >30 s
 - 2 measurements at least 1 min apart
- No orthostatic hypotension
 (↓ ≥20/10 mmHg by 3 min)

Chronic

- ≥6 months
- >3 months
 - CanadianCVSociety



Associated with Symptoms

Orthostatic

- Lightheadedness
- Palpitations
- Tremulousness
- Atypical chest discomfort

Not orthostatic

- Fatigue
- Blurred vision
- Pre-syncope
- Bloating, diarrhea, constipation
- Headache
- Brain fog
- Exercise intolerance

Absence of other conditions

- Acute dehydration
- Infection
- Anemia
- Hyperthyroidism
- Pheochromocytoma
- Medications-induced
- Recreational drugs effects
- Sustained bed rest
- Anxiety or panic attacks




Lei LY et al. Cleveland Clinic J Med. 2019;86:333-344. Aboseit DO et al. Cleveland Clinic J Med. 2023;90:439-477.

Physical Exam


"POTS feet"

Acrocyanosis (dark, red-blue discoloration of lower legs that is cold to touch (~50%)






Basic Laboratory and Other Tests




- CBC
- Basic metabolic panel
- TSH, free T4
- Ferritin
- AM cortisol



ECG


- Sinus tachycardia
- Atrial tachycardia
- Multifocal atrial tachycardia



CONTINUOUS MONITOR


- Arrhythmia
- Inappropriate sinus tachycardia
 - >100 bpm at rest supine and standing
 - Mean 24-hour rate >90 bpm and associated with palpitations

POTS Subtypes




Narasimhan B et al. Vascular Health and Risk Management. 2023;19:303-3016.

POTS Downward Spiral



Adapted from Bryarly M et al. JACC. 2019;73:1207-1228.


Hypovolemic POTS




Neuropathic POTS

~ 50% prevalence

Sympathetic denervation, lower limbs
Lower supine/standing heart rate
Less anxiety and depression







Hyperadrenergic POTS


Tricyclic antidepressant (nortriptyline)

Serotonin-norepinephrine reuptake inhibitors (bupropion)

Attention-deficit disorder medications (methylphenidate)

~ 50% prevalence

Palpitations, anxiety, tremulousness, hyperhidrosis



High standing norepinephrine levels (≥ 600 – 1,000 pg/mL)

↑ Systolic blood pressure ≥ 10 mmHg within 10 min of standing


- ↓ Norepinephrine transporter density (rare genetic mutation)
- ↓ Norepinephrine clearance of synaptic norepinephrine
 - ↑ Sympathetic nerve activation

Lei LY et al. Cleveland Clinic J Med. 2019;86:333-344.

Mast Cell Activation Syndrome

9% prevalence

- Strong allergic symptoms
- Food sensitivities
- Dermatographism
- Frequent urticaria
- Severe Flushing
- Shortness of breath
- Neuropathy




Histamine release

↑ Urine methylhistamine

> 230 µg/g creatinine in 4 h urine collection



Autoimmune POTS



16% prevalence


- Preceding viral illness
- 7% Antiphospholipids antibodies
- 6% Hashimoto thyroiditis
- 3% Celiac disease
- 3% Sjögren syndrome
- 2% Rheumatoid arthritis
- 2% SLE

- 87% prevalence auto antibodies to M1, M2, and M3 muscarinic receptors
- 25% prevalence antinuclear antibodies
- Cardiac lipid-raft-associated proteins (cardiac dysautonomia)
- Adrenergic G-protein coupled receptors antibodies
 - α₁-adrenergic receptors
 - B₁- and β_2 -adrenergic receptors
- Angiotensin II type 1 receptor antibodies



Possible Underlying Mechanism of Long COVID-19 and POTS Long COVID-19 ↓ Blood Volume & Neural propagation of Inflammatory & Deconditioning of the heart COVID-19 Autoimmunity Dysautonomia **POTS** Adapted from Sebastian SA et al. Curr Prob Cardiol. 2022;47:1-24

POTS and Related Disorders







Co-existing Conditions with POTS

Fibromyalgia

20%



75% of POTS – fatigue



Functional GI disorders IBS Celiac 3% Anxiety &

Hypervigilance

Type III Ehlers-Danlos Syndrome

- Joint hypermobility
 - Autonomic dysregulation
- Skin hyperextensibility
- Tissue fragility



Bryarly M et al. JACC. 2019;73:1207-1228. Raj SR et al. Can J Cardiol. 2020;36:357-372.


Differential Diagnoses

- Hyperthyroidism
- Infection
- Pheochromocytoma
 - Palpitations, lightheadedness, flushing while supine
 - Plasma norepinephrine higher than POTS
 - ↑ Metanephrines
- Inappropriate sinus tachycardia
 - HR ≥ 100 bpm at rest
 - Mean 24-hour heart rate ≥ 90 bpm
 - Associated with palpitations

- Acute dehydration
- Exercise
- Physical deconditioning
- Panic attacks
- Pain
- Alcohol
- Caffeine
- Medication-induced or exacerbated




Diagnostic Algorithm






Diagnostic Algorithm – Referral?




Nonpharmacologic Treatment Options





Raj SR et al. Can J Cardiol. 2020;36:357-372. Bryarly M et al. JACC. 2019;73:1207-1228. Sebastian SA et al. Curr Prob Cardiol. 2022;47:1-24

Case - Management




Nonpharmacologic Therapies

Therapy	Dosage	Pathologic mechanisms addressed	Potential drawbacks	Comments
Exercise	≥ 30 min at least 3 times a week	All	Worsened symptoms at the outset, prolonged fatigue	Gradually progress from non- upright to upright endurance and resistance exercises
Dietary fluid	2–3 L per day	All	Hyponatremia	
Dietary salt	10–12 g per day	All	Difficult to augment suffi- ciently through diet alone	Supplement with sodium chloride tablets, if necessary
Compression stockings	Waist high 30 40 mmHg	All	Difficult to put on	
Sleep with head elevation	4-6 inches	All		
Salt tablets	1 g tablet 3 times daily	Hypovolemia	Poor taste, nausea, dyspepsia	Recommended for use after meals
Acute intravenous normal saline	1 L over 1–3 hours	Hypovolemia	Inconvenient, medical setting required	Heart Rhythm Society Consensus Statement class IIa recommenda- tion (benefit probably exceeds risk)
Chronic intravenous normal saline	1 L every 2 days	Hypovolemia	Access complications and infection with central line	Heart Rhythm Society Consensus Statement class III recommendation (recommends against)



Compression Garments




N= 26 female

Age: 16-54 years old

Race: White n=21; South Asian n=1; Indigenous n=1, Multiple n=3 Meds:

- Beta-blockers (71%, n=17)
- Midodrine (31%, n=8)
- Pyridostigmine (12%, n=3)


Commercial medical compression garment (65%, n=17) Athletic style (17%, n=4)



Compression Garments

NO MEDICINE

WITH MEDICINE



Bourne KM et al. JACC Clin Electrophysiol. 2024

Exercise Prescription


Endurance:

- 5 min warm-up, 5 min cool-down
- Recumbent
 - 3-4 times/week for 25-30 min for 2 months
- Upright bike or walking on treadmill
 - 5-6 times/week for 45-60 min


Resistance

- Weight-lifting once/week,
 15-20 min/session
- Increase 2 times/week, 30-40 min/session

Adapted from Rudofker EW et al. J Am Coll Cardiol Case Rep. 2022;4:31344-1347.



Treatment Algorithm - Pharmacotherapy



Pharmacologic Therapies

NO medication has been FDA-approved specifically for POTS. The following medications have been studied in clinical trials

Therapy	Dosage	Pathologic mechanism addressed	Potential drawbacks	Comments	
Blood volume expanders					
Fludro- cortisone IIb	0.05–0.1 mg twice daily	Hypovolemia	Hypokalemia, hypertension, fatigue, headache, fluid retention, edema		
Desmopressin	0.1–0.2 mg 3 times daily	Hypovolemia	Hyponatremia, headache, edema	Only for occasional use; must monitor blood sodium, 1x/week	
Erythro- poietin	2,000–3,000 IU subcutaneously 1–3 times per week	Hypovolemia	High cost, requires injection, risk of vascular complications	Reserved for patients with symptoms refractory to more common treatments	
Heart rate-lowering agents					
Propranolol IIb	10–20 mg 3–4 times daily	All	Hypotension, fatigue, drowsiness, wheezing	Not well tolerated at higher dosages	
Ivabradine	5–7.5 mg twice daily	All	Palpitations, headache, dizziness, constipation		




Pharmacologic Therapies

Therapy	Dosage	Pathologic mechanism addressed	Potential drawbacks	Comments
Clonidine	0.05–0.2 mg twice daily	Hyperadrenergic	Mental clouding, fatigue, drowsi- ness, constipation	Can be associated with rebound hypertension and tachycardia
Methyldopa	125 mg once or twice daily	Hyperadrenergic	Hypotension, fatigue, headache, drowsiness, constipation	Rare lupus-like syndrome reported
Other drugs				15-30 min before getting out of bed in AM
Midodrine IIb	2.5-15 mg every 4 hours, 3 times daily only	Neuropathic	Hypertension, goose bumps, urinary retention	Not recommended for use within 4-5 hours of sleep
Pyrido- stigmine IIb	30–60 mg 3 times daily	All	Abdominal cramping, diarrhea, increased sweating	May increase gastrointesti- nal motility
Droxidopa	100–600 mg 3 times daily	All	Nausea, palpitations, urinary symptoms	May worsen tachycardia
Modafinil	100–200 mg twice daily	"Brain fog"	Headache, dizziness, anxiety, insomnia	May improve cognitive symptoms
H ₁ and H ₂ histamine receptor blockers			Avoid concomitant beta-blocker	Drowsiness, dizziness




Case - Management

COVID-19 infection



- PICC
- IVF infusion 3-4 times/weeks
- Propranolol changed to metoprolol succinate 50 mg BID
- Metop tartrate 12.5 mg QID prn
- Removed PICC #2
- Compression stockings
- Physical therapy





Case - Management

- Tachycardia
- Diagnosed with POTS
- PICC
- IVF infusion 3-4 times/weeks
- Propranolol changed to metoprolol succinate 50 mg BID
- Metop tartrate 12.5 mg QID prn
- Removed PICC #2
- Compression stockings
- Physical therapy

- Advance recumbent exercise regimen
- Liberal fluid intake
- Waist-high compression garment
- Ivabradine 5 mg BID

2019 2021

2023

2025

2020

- Standing HR 130-200s
- Standing > 5 min --> dizziness
- Uses wheelchair
- COVID-19 infection

2022

- PICC #1 infected
- PICC #2 inserted

2024

- D/C metoprolol
- Start ivabradine 5 mg BID
- Start recumbent exercise regimen



Key Points

- Heterogeneous presentation
- Features overlap with other conditions
- 80% occur in premenopausal women
- Etiology and pathophysiology of POTS are not fully understood
- Clinical diagnosis: history, exam, basic diagnostic tests
- Graded treatment:
 - Avoid known triggers
 - Optimize fluid and salt intake
 - Compression garments
 - Regimented exercise program
 - Pharmacotherapy for refractory symptoms
 - ➤ Personalize medication according to POTS subtype

